Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin

E Ben-Menachem1

  • 1Department of Neurology, Sahlgren University Hospital, Göteborg, Sweden.

Epilepsia
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

gamma-Aminobutyric acid (GABA) is an inhibitory neurotransmitter. Enhancing GABA function can treat epilepsy, though the relationship is complex. Vigabatrin effectively increases brain GABA levels and acts as an antiepileptic drug.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.

Acta neurologica Scandinavica·2018
Same author

The effect of a multifaceted postoperative nausea and vomiting reduction strategy on prophylaxis administration amongst higher-risk adult surgical patients.

Anaesthesia and intensive care·2018
Same author

Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.

Journal of neurology·2017
Same author

Alcohol withdrawal syndrome: mechanisms, manifestations, and management.

Acta neurologica Scandinavica·2016
Same author

Long-term adjunctive lacosamide treatment in patients with partial-onset seizures.

Acta neurologica Scandinavica·2015
Same author

Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability.

European journal of neurology·2015
Same journal

Psychological stress during wartime and its association with seizure-related emergency department utilization.

Epilepsia·2026
Same journal

WONOEP appraisal: Biomarkers and treatment strategies beyond the synapse.

Epilepsia·2026
Same journal

Does electrocorticographic guidance improve seizure outcomes following cavernoma resection?

Epilepsia·2026
Same journal

Raising resilience: A parenting intervention for families affected by childhood epilepsy.

Epilepsia·2026
Same journal

Epileptogenic lesions in the Australian epilepsy project: A harmonized 3-T magnetic resonance imaging protocol and its diagnostic yield.

Epilepsia·2026
Same journal

Responsible use of artificial intelligence in peer-reviewed publications in epilepsy.

Epilepsia·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • gamma-Aminobutyric acid (GABA) is recognized as a key inhibitory neurotransmitter.
  • Decreased GABA levels are linked to convulsions, while enhanced GABA function shows antiepileptic potential.
  • The precise relationship between GABA levels and seizure activity is complex and may involve regional brain differences.

Purpose of the Study:

  • To explore strategies for increasing GABA at receptor sites to develop effective antiepileptic treatments.
  • To review compounds developed since the 1970s that modulate the GABA system for antiepileptic effects.
  • To highlight Vigabatrin (VGB) as a specific antiepileptic drug designed to increase brain GABA availability.

Main Methods:

  • Investigating agents that enhance GABA-mediated inhibition.

Related Experiment Videos

  • Developing compounds that target different levels of the GABA system, including agonist properties, inhibition of catabolism or uptake, and facilitation of release or receptor activity.
  • Designing Vigabatrin to specifically inhibit GABA transaminase.

    • Main Results:

    • Antiepileptic effects depend on the mechanism of GABA-mediated inhibition enhancement.
    • Various compounds targeting the GABA system exhibit diverse effects based on their mechanism of action.
    • Vigabatrin has been demonstrated as an effective antiepileptic drug through 14 years of study and clinical experience.

    Conclusions:

    • Modulating the GABA system offers a viable therapeutic strategy for epilepsy.
    • Vigabatrin's targeted inhibition of GABA transaminase effectively increases brain GABA and provides antiepileptic benefits.
    • Further research into GABAergic mechanisms is crucial for advancing epilepsy treatment.